MarketCap
Mirum Pharmaceuticals MIRM
$ 93.81
0.39%
Facebook
X
Telegram
Mirum Pharmaceuticals ROE Ratio | MIRM
Annual ROE Ratio Mirum Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.42 | -38.97 | -65.72 | -95.51 | -69.87 | -60.01 | -40.32 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.42 | -95.51 | -53.97 |
Quarterly ROE Ratio Mirum Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 392.62 | 318.38 | -328.97 | -9.42 | -18.14 | -25.27 | -33.73 | -38.21 | -42.01 | -44.64 | -128.07 | -138.64 | -149.95 | -162.27 | -92.41 | -104.67 | -31.15 | -93.59 | -115.11 | -119.25 | -188.74 | -123.09 | -94.31 | -70.22 | -62.38 | -54.81 | 1.06 | 10.14 | 24.3 | 34.68 | -4.57 | - | 0.39 | 0.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 392.62 | -328.97 | -45.21 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
SIGA Technologies
SIGA
|
11.71 | $ 3.12 | 4.55 % | $ 223 M |  USA |
 |
Sage Therapeutics
SAGE
|
-86.15 | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.47 | - | - | $ 1.62 B |  Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-26.86 | $ 61.62 | -2.21 % | $ 172 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
-37.9 | $ 8.41 | 6.73 % | $ 917 M | USA |
 |
Summit Therapeutics
SMMT
|
-163.86 | $ 16.34 | 15.15 % | $ 12.2 B |  Britain |
 |
Cabaletta Bio
CABA
|
-149.81 | $ 1.3 | 1.17 % | $ 131 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-441.62 | $ 9.53 | 1.39 % | $ 826 M | USA |
 |
Sanofi
SNY
|
10.95 | $ 47.06 | 0.32 % | $ 57.4 B |  France |
 |
Forma Therapeutics Holdings
FMTX
|
-34.71 | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-22.46 | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
10.28 | - | - | $ 26.6 B |  Irlanda |
 |
Sarepta Therapeutics
SRPT
|
-62.55 | $ 17.8 | 0.68 % | $ 1.78 B | USA |
 |
Paratek Pharmaceuticals
PRTK
|
37.16 | - | - | $ 121 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-20.89 | $ 2.84 | -3.07 % | $ 1.93 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
1.56 | $ 21.02 | -0.92 % | $ 33.2 B |  Japan |
 |
Tarsus Pharmaceuticals
TARS
|
-19.22 | $ 68.11 | 0.87 % | $ 2.85 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
332.81 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Bio-Techne Corporation
TECH
|
8.63 | $ 72.78 | 0.17 % | $ 11.4 B | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
17.83 | $ 42.32 | 1.33 % | $ 48.5 B | Israel |
 |
RedHill Biopharma Ltd.
RDHL
|
176.55 | $ 0.43 | 0.45 % | $ 5.3 B | Israel |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-400.22 | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-22.77 | - | - | $ 411 M | USA |
 |
Shattuck Labs
STTK
|
-59.24 | $ 4.59 | 2.78 % | $ 319 M | USA |
 |
Seelos Therapeutics
SEEL
|
113.05 | - | -47.76 % | $ 6.27 M | USA |
 |
Evogene Ltd.
EVGN
|
-65.36 | $ 0.28 | -16.14 % | $ 2.2 M | Israel |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Protara Therapeutics
TARA
|
-29.22 | $ 2.33 | 9.15 % | $ 99.8 M | USA |
 |
Trevi Therapeutics
TRVI
|
-23.34 | $ 14.33 | 11.87 % | $ 1.93 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-65.32 | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
-27461.1 | $ 9.79 | 4.26 % | $ 280 M | USA |
 |
Kiromic BioPharma
KRBP
|
213.7 | - | 6.61 % | $ 3.08 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-350.48 | $ 3.92 | -2.24 % | $ 1.74 M | USA |
 |
Calithera Biosciences
CALA
|
-194.44 | - | -10.95 % | $ 876 K | USA |
 |
United Therapeutics Corporation
UTHR
|
18.81 | $ 562.14 | -0.63 % | $ 24.9 B | USA |
 |
Vericel Corporation
VCEL
|
4.66 | $ 54.56 | 5.36 % | $ 2.75 B | USA |
 |
Veracyte
VCYT
|
5.07 | $ 24.1 | 0.42 % | $ 1.89 B | USA |
|
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-21.46 | $ 3.72 | 0.95 % | $ 236 M | USA |
 |
Molecular Templates
MTEM
|
-192.88 | - | -23.43 % | $ 495 K | USA |
 |
Vanda Pharmaceuticals
VNDA
|
-67.39 | $ 3.82 | 6.27 % | $ 225 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-72.34 | $ 3.22 | 4.21 % | $ 34.3 M | USA |
 |
Viridian Therapeutics
VRDN
|
-47.44 | $ 28.47 | -0.28 % | $ 2.9 B | USA |
 |
BioXcel Therapeutics
BTAI
|
73.22 | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
VistaGen Therapeutics
VTGN
|
-196.19 | $ 0.17 | 3.45 % | $ 6.47 M | USA |
 |
Voyager Therapeutics
VYGR
|
-61.06 | $ 1.86 | 8.14 % | $ 109 M | USA |
 |
CohBar
CWBR
|
-79.41 | - | -15.44 % | $ 2.2 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-23.97 | - | -1.56 % | $ 12.3 M | USA |
 |
Gossamer Bio
GOSS
|
138.78 | $ 9.77 | 3.72 % | $ 2.23 B | USA |